10-K: Atossa Therapeutics Reports 2024 Results, Focuses on Metastatic Breast Cancer Indication

Atossa Therapeutics' 2024 10-K filing reveals a strategic shift towards a metastatic breast cancer indication for (Z)-endoxifen, alongside ongoing Phase 2 trials and financial updates.

Summary

• Atossa Therapeutics, a clinical-stage biopharmaceutical company, is focusing on developing medicines for oncology, particularly women's breast cancer.
• Their lead drug candidate is oral (Z)-endoxifen, being developed for breast cancer prevention and treatment.
• The company is currently investigating (Z)-endoxifen in four Phase 2 trials: EVANGELINE, Karisma-(Z)-endoxifen, I-SPY 2 EOP, and RECAST DCIS.
• A strategic decision was made to pursue a metastatic breast cancer indication for (Z)-endoxifen, potentially offering a more efficient regulatory pathway.
• The company estimates the global ER+ breast cancer treatment market to reach $33.7 billion by 2030.
• As of December 31, 2024, Atossa had approximately $71.1 million in cash and cash equivalents.
• The company plans to obtain additional capital through equity sales and borrowing.
• Research and development expenses for 2024 were approximately $14.1 million, compared to $17.3 million in 2023.
• As of February 3, 2025, Atossa owns 13 issued patents and is pursuing 119 pending patent applications related to its therapies.
• The company relies on third-party contractors for manufacturing, clinical studies, and associated operations.
• Atossa is subject to extensive regulation by the FDA and other agencies.
• The company employs two executive officers and thirteen full-time employees as of the report date.
• The company incurred net losses of approximately $25.5 million and $30.1 million for the years ended December 31, 2024 and 2023, respectively.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments in clinical trials and a strategic shift towards a potentially more efficient regulatory pathway, the company's ongoing losses and dependence on raising additional capital create uncertainty.

Positives

• The Karisma-(Z)-endoxifen study demonstrated significant reductions in mammographic breast density with low-dose (Z)-endoxifen.
• Preliminary data from the I-SPY 2 EOP trial showed promising activity of (Z)-endoxifen in reducing key biomarkers.
• The company is actively pursuing multiple Phase 2 trials for (Z)-endoxifen in various breast cancer settings.
• Atossa has a strong intellectual property portfolio with 13 issued patents and 119 pending applications.
• The company has a significant cash position of $71.1 million as of December 31, 2024.

Negatives

• Atossa has a history of operating losses and expects to continue incurring losses in the future.
• The company has not established an ongoing source of revenue sufficient to cover operating costs.
• The company is dependent on raising additional capital to fund its operations.
• The company incurred a $1.7 million impairment charge related to its investment in Dynamic Cell Therapies, Inc. (DCT) in 2024.
• The PTAB issued a final written decision that found that all claims under the Patent were unpatentable.

Risks

• The company's ability to continue as a going concern is dependent on obtaining adequate capital.
• Clinical trials may fail to demonstrate the efficacy and safety of product candidates.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company is dependent on third-party service providers for critical operational activities.
• Legislative or regulatory reforms may make it more difficult and costly to obtain regulatory approval.
• The company's ability to use net operating loss carryforwards and research tax credits may be limited.
• The company's shares of common stock are listed on the Nasdaq Capital Market, but there is no guarantee that the company will be able to regain compliance with the continued listing standards or satisfy the continued listing standards going forward.

Future Outlook

Atossa plans to advance its programs through clinical studies, potentially with partners, and opportunistically add programs in areas of high unmet medical need. The company is focusing on a metastatic breast cancer indication for (Z)-endoxifen and plans to work with the FDA to advance additional indications.

Management Comments

• Atossa believes that pursuing a metastatic indication may offer a more efficient regulatory pathway to deliver (Z)-endoxifen to women in urgent need.
• Atossa simultaneously plans to work with the FDA to advance additional indications, such as breast cancer prevention and neoadjuvant therapy, that often require larger and longer clinical trials.

Industry Context

The announcement aligns with the growing focus on targeted therapies and personalized medicine in the oncology space, particularly in breast cancer treatment and prevention. The company is positioning (Z)-endoxifen as a potential alternative to tamoxifen, addressing its limitations and side effects.

Comparison to Industry Standards

• The global ER+ breast cancer treatment market is anticipated to reach $33.7 billion by 2030, reflecting the significant unmet need and commercial opportunity in this area.
• The company's focus on (Z)-endoxifen, a SERM, aligns with established treatment approaches for ER+ breast cancer, but aims to improve upon existing therapies like tamoxifen.
• The I-SPY 2 trial is a well-regarded platform trial for evaluating neoadjuvant breast cancer therapies, providing a collaborative and efficient approach to drug development.
• The company's participation in the I-SPY 2 EOP trial alongside Eli Lilly's abemaciclib (VERZENIO) demonstrates a commitment to exploring combination therapies and addressing unmet needs in ER+/HER2breast cancer.

Legal Proceedings

• Intas Pharmaceuticals LTD. filed a Petition for Post Grant Review (PGR) with the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office, the (PGR Petition), seeking to invalidate all claims related to one of the Company's issued patents (U.S. Patent No. 11,572,334) titled 'Methods for Making and Using Endoxifen', (the Patent), on the grounds of anticipation and obviousness.
• On January 29, 2025, the PTAB issued a Final Written Decision (the PTAB Decision) finding all challenged claims under the Patent unpatentable.

Stakeholder Impact

• Shareholders: Dilution may occur from future equity sales.
• Patients: Potential for new treatment options for breast cancer.
• Employees: Continued employment and potential for growth within the company.

Next Steps

• Initiate the Treatment Cohort of the EVANGELINE trial in the first half of 2025.
• Continue enrollment in the I-SPY 2 EOP trial evaluating (Z)-endoxifen in combination with abemaciclib.
• Continue enrollment in the RECAST DCIS Phase 2 platform study.
• Conduct additional studies of (Z)-endoxifen to assess its correlation with the risk of breast cancer and/or reduction in the incidence of new breast cancers.
• Work with the FDA to advance additional indications, such as breast cancer prevention and neoadjuvant therapy.

Key Dates

Keywords

Z-endoxifen, breast cancer, clinical trials, metastatic, mammographic breast density, ER+, HER2-, FDA, patents, biopharmaceutical